MedPath

Clinical study of Rongqingbaohuashuan powder on patients with carotid atherosclerosis

Phase 2
Conditions
Hyperlipidemia
Registration Number
ITMCTR2100005121
Lead Sponsor
Qilu Hospital of Shandong University
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Pending
Sex
All
Target Recruitment
Not specified
Inclusion Criteria

1. Sign the informed consent form and be aged 40 to 65 years on the day;
2. Fasting low-density lipoprotein cholesterol (LDL-C) >=3.4mmol/L;
3. Fasting triglyceride <=5.6 mmol/L during screening;
4. Carotid ultrasound showed carotid atherosclerotic plaque.

Exclusion Criteria

1. Those who are allergic to any ingredient in statin or Rongqingbaohua suppository powder food;
2. Those with a history of hypertension and diabetes and a definite diagnosis;
3. Rheumatic immune diseases, malignant tumors, etc.;
4. Various acute and chronic infectious diseases and acute metabolic disorders;
5. Chronic bronchitis, chronic obstructive pulmonary disease, etc.;
6. Liver function alanine aminotransferase (ALT) or aspartate aminotransferase (AST) or total bilirubin is higher than the upper limit of normal;
7. Creatine kinase (CK) is higher than the upper limit of normal;
8. Estimated glomerular filtration rate (eGFR) <= 90ml/min/1.73m2 (calculated by MDRD formula);
9. Those who are currently taking various lipid-lowering drugs (including Western medicines, Chinese patent medicines and other drugs and health care products with lipid-lowering effects).

Study & Design

Study Type
Interventional study
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Carotid atherosclerotic plaque;blood fat;
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath